Liminatus Pharma, Inc. (LIMN)

Liminatus Pharma, Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology. Its pipeline centers on therapies targeting CD47, a protein that cancer cells use to signal macrophages not to engulf them, with the goal of helping the immune system recognize and destroy tumors.

The company became a public company through a business combination with a special purpose acquisition company, and its Class A common stock trades on the Nasdaq under the ticker LIMN.